Assessing health outcomes: a systematic review of electronic patient-reported outcomes in oncology.

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY European journal of hospital pharmacy : science and practice Pub Date : 2024-12-30 DOI:10.1136/ejhpharm-2023-004072
Mikel Urretavizcaya, Karen Álvarez, Olatz Olariaga, Maria Jose Tames, Ainhoa Asensio, Gerardo Cajaraville, Ana Cristina Riestra
{"title":"Assessing health outcomes: a systematic review of electronic patient-reported outcomes in oncology.","authors":"Mikel Urretavizcaya, Karen Álvarez, Olatz Olariaga, Maria Jose Tames, Ainhoa Asensio, Gerardo Cajaraville, Ana Cristina Riestra","doi":"10.1136/ejhpharm-2023-004072","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the clinical impact of electronic patient-reported outcome (ePRO) monitoring apps/web interfaces, aimed at symptom-management, in cancer patients undergoing outpatient systemic antineoplastic treatment. Additionally, it explores the advantages offered by these applications, including their functionalities and healthcare team-initiated follow-up programmes.</p><p><strong>Methods: </strong>A systematic literature review was conducted using a predefined search strategy in MEDLINE. Inclusion criteria encompassed primary studies assessing symptom burden through at-home ePRO surveys in adult cancer patients receiving outpatient systemic antineoplastic treatment, whenever health outcomes were evaluated. Exclusion criteria excluded telemedicine-based interventions other than ePRO questionnaires and non-primary articles or study protocols. To evaluate the potential bias in the included studies, an exhaustive quality assessment was conducted, as an additional inclusion filter.</p><p><strong>Results: </strong>Among 246 identified articles, 227 were excluded for non-compliance with inclusion/exclusion criteria. Of the remaining 19 articles, only eight met the rigorous validity assessment and were included for detailed examination and data extraction, presented in attached tables.</p><p><strong>Conclusion: </strong>This review provides compelling evidence of ePRO monitoring's positive clinical impact across diverse cancer settings, encompassing various cancer types, including early and metastatic stages. These systems are crucial in enabling timely interventions and reducing communication barriers, among other functionalities. While areas for future ePRO innovation are identified, the primary limitation lies in comparing clinical outcomes of reviewed articles, due to scale variability and study population heterogeneity. To conclude, our results reaffirm the transformative potential of ePRO apps in oncology and their pivotal role in shaping the future of cancer care.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of hospital pharmacy : science and practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2023-004072","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This study investigates the clinical impact of electronic patient-reported outcome (ePRO) monitoring apps/web interfaces, aimed at symptom-management, in cancer patients undergoing outpatient systemic antineoplastic treatment. Additionally, it explores the advantages offered by these applications, including their functionalities and healthcare team-initiated follow-up programmes.

Methods: A systematic literature review was conducted using a predefined search strategy in MEDLINE. Inclusion criteria encompassed primary studies assessing symptom burden through at-home ePRO surveys in adult cancer patients receiving outpatient systemic antineoplastic treatment, whenever health outcomes were evaluated. Exclusion criteria excluded telemedicine-based interventions other than ePRO questionnaires and non-primary articles or study protocols. To evaluate the potential bias in the included studies, an exhaustive quality assessment was conducted, as an additional inclusion filter.

Results: Among 246 identified articles, 227 were excluded for non-compliance with inclusion/exclusion criteria. Of the remaining 19 articles, only eight met the rigorous validity assessment and were included for detailed examination and data extraction, presented in attached tables.

Conclusion: This review provides compelling evidence of ePRO monitoring's positive clinical impact across diverse cancer settings, encompassing various cancer types, including early and metastatic stages. These systems are crucial in enabling timely interventions and reducing communication barriers, among other functionalities. While areas for future ePRO innovation are identified, the primary limitation lies in comparing clinical outcomes of reviewed articles, due to scale variability and study population heterogeneity. To conclude, our results reaffirm the transformative potential of ePRO apps in oncology and their pivotal role in shaping the future of cancer care.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估健康结果:肿瘤学患者电子报告结果的系统性回顾。
目的:本研究调查了电子患者报告结果(ePRO)监测应用程序/网络界面对接受门诊系统性抗肿瘤治疗的癌症患者症状管理的临床影响。此外,该报告还探讨了这些应用程序的优势,包括其功能和医疗团队发起的后续计划:方法:采用预先确定的 MEDLINE 搜索策略进行了系统性文献综述。纳入标准包括通过对接受门诊系统性抗肿瘤治疗的成年癌症患者进行居家 ePRO 调查来评估症状负担的主要研究,并对健康结果进行评估。排除标准不包括 ePRO 问卷以外的基于远程医疗的干预措施,也不包括非主要文章或研究方案。为评估所纳入研究的潜在偏倚,还进行了详尽的质量评估,作为额外的纳入筛选:在 246 篇已确定的文章中,有 227 篇因不符合纳入/排除标准而被排除。在剩余的 19 篇文章中,只有 8 篇符合严格的有效性评估要求,并被纳入进行详细审查和数据提取,详情见附表:本综述提供了令人信服的证据,证明 ePRO 监测在不同的癌症治疗环境中具有积极的临床影响,涵盖各种癌症类型,包括早期和转移期癌症。除其他功能外,这些系统对实现及时干预和减少沟通障碍至关重要。虽然确定了未来 ePRO 创新的领域,但由于规模的差异性和研究人群的异质性,主要的局限性在于比较综述文章的临床结果。总之,我们的研究结果再次证实了 ePRO 应用程序在肿瘤学领域的变革潜力,以及它们在塑造未来癌症治疗中的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
5.90%
发文量
104
审稿时长
6-12 weeks
期刊介绍: European Journal of Hospital Pharmacy (EJHP) offers a high quality, peer-reviewed platform for the publication of practical and innovative research which aims to strengthen the profile and professional status of hospital pharmacists. EJHP is committed to being the leading journal on all aspects of hospital pharmacy, thereby advancing the science, practice and profession of hospital pharmacy. The journal aims to become a major source for education and inspiration to improve practice and the standard of patient care in hospitals and related institutions worldwide. EJHP is the only official journal of the European Association of Hospital Pharmacists.
期刊最新文献
Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib. Influence of volume and citrate on perceived pain in patients treated with adalimumab. Monitoring of occupational exposure to hazardous medicinal products in robotic compounding. Feasibility study of the digital tool Max for the patient-provided medication list in the medication reconciliation process prior to hospitalisation: patient willingness and usability, time saved and reliability. Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unit.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1